NMPA Approves Implantable Cardiac Event Monitor and Intracranial Stent as Innovative Medical Devices

The National Medical Products Administration (NMPA) continues to drive medical device innovation, with multiple innovative products recently approved for market launch. The cumulative number of approved innovative medical devices in China has reached a new milestone.

Latest Approvals (July 2026)

1. Implantable Cardiac Event Monitor (ICM)

l Manufacturer: Suzhou Wushuang Medical Device Co., Ltd.

l Approval Date: July 1, 2026

l Product Description: Consists of an implantable cardiac event monitor (ICM) and a patient activator. Used for recording subcutaneous electrocardiograms in patients with clinical symptoms, transient symptoms, or those at increased risk of arrhythmias

l Innovation Significance: First domestically developed ICM, filling a critical gap in China's medical device landscape

2. Intracranial Stent

l Manufacturer: Synergy Medical Technology (Shanghai) Co., Ltd.

l Approval Date: July 2, 2026

l Product Description: Features a closed-cell helical mesh splicing design, closed-loop design, and full visualization design. Used in conjunction with embolization devices for treating intracranial anterior circulation saccular wide-neck aneurysms

l Key Innovations: Excellent flexibility and wall apposition, retrievable and repositionable, precise positioning

As of July 2026, China has approved over 430 innovative medical devices cumulatively. In 2026 alone, 52 innovative devices have been approved. A total of 76 domestically developed innovative medical devices were approved in 2025, maintaining high volume for three consecutive years.

Approved products span cutting-edge fields including genetic sequencing, AI-assisted diagnostics, surgical robotics, cardiovascular interventions, neuromodulation, and oncology treatments.

The NMPA continues to optimize the Innovative Medical Device Special Review Procedure, providing a "green channel" for innovative products. In 2026, the administration introduced ten measures to strongly support the development of high-end medical devices including medical robots. Drug regulatory authorities will strengthen post-market supervision to ensure patient safety.